Drugs / GW842166X
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00554762 | Nov 2007 → Mar 2008 | — | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00536497 | Sep 2007 → ? | — | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00511524 | Jun → Jul 2007 | inflammatory disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00479427 | Jul → Oct 2007 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00447486 | Apr 2007 → ? | osteoarthritis, knee | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00444769 | Oct 2006 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW842166X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00511524 ↗ |
| Known as | GW842166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00447486 ↗ |
| Action | Activate | “Non-Cannabinoid CB2 Receptor Agonist” NCT00444769 ↗1“Cannabinoid CB2 receptor agonist” CHEMBL225411 ↗ |
| Modality | Small molecule | — CHEMBL225411 ↗ |
| Route | Oral | “single pre-operative oral dose” NCT00444769 ↗ |
| Target | CNR2 | “Cannabinoid CB2 receptor agonist” CHEMBL225411 ↗ |